- Peptide Generic API
- Peptide NCEs
Peptide API CMO Market was valued at USD 1,756.0 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2029. The pharmaceutical companies are driving the growth of the peptide API CMO market by seeking reliable partners to meet their growing manufacturing needs. One key driver is the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has spurred the development of peptide-based therapeutics. According to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality worldwide, with an estimated 10 million deaths in 2020. As the demand for effective treatments for these diseases continues to rise, pharmaceutical companies are increasingly turning to CMOs to fulfil their peptide API manufacturing requirements.
Moreover, the increasing complexity and regulatory scrutiny associated with peptide drug development pose challenges for pharmaceutical companies, driving them to seek external expertise and support. CMOs with a track record of successfully navigating regulatory requirements and delivering high-quality peptide APIs are in high demand as pharmaceutical companies strive to bring innovative therapies to market efficiently. In conclusion, the peptide API CMO market is driven the rising prevalence of chronic diseases and the need for external expertise and support in drug development. As the demand for peptide-based therapeutics continues to grow, the market is poised for significant expansion in the coming years.
Study Period
2024-2030Base Year
2023CAGR
7.2%Largest Market
North AmericaFastest Growing Market
Asia-Pacific
In recent years, the demand for peptide drugs has surged, leading to a significant expansion in the peptide API Contract Manufacturing Organization (CMO) market. This growth is propelled by several key supply-side drivers that are reshaping the landscape of peptide manufacturing. One crucial driver is the increasing complexity of peptide APIs and the specialized expertise required for their production. Peptide drugs are becoming more intricate in their molecular structures, often requiring advanced synthesis techniques and specialized equipment for manufacturing. As a result, pharmaceutical companies are turning to CMOs with extensive experience and capabilities in peptide synthesis to meet their manufacturing needs. Furthermore, the shift towards personalized medicine and the development of targeted peptide therapies for various diseases such as cancer, diabetes, and autoimmune disorders is fueling demand for specialized peptide manufacturing services. As pharmaceutical companies focus on developing tailored treatments for specific patient populations, they rely on CMOs with the expertise to produce custom peptide APIs efficiently. The significant driver is the increasing adoption of outsourcing by pharmaceutical companies to streamline their operations and reduce costs. Outsourcing peptide manufacturing to CMOs allows pharmaceutical companies to leverage the expertise and infrastructure of specialized manufacturers without investing in expensive equipment and facilities themselves.
By Product Type
By Therapeutic area
By End User
By Geography
The peptide API CMO market was valued at USD 1,756.0 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2030.
Expansion of peptide therapeutic applications and advancements in peptide delivery technologies is expected to provide opportunities to the market players in the market growth over the forecast period.
The leading players in the global Peptide API CMO Market are ScinoPharm Taiwan, Ltd., Corden Pharma International, Bachem AG, Biopeptek Pharmaceuticals LLC., Hybio Pharmaceutical Co., Ltd., Chinese Peptide Company, AmbioPharm, Inc., Teva Pharmaceutical Industries Ltd. PolyPeptide Group, Chemi S.p.A.
1. Executive Summary |
2. Global Peptide API CMO Market Introduction |
2.1. Global Peptide API CMO Market - Taxonomy |
2.2. Global Peptide API CMO Market -Definitions |
2.2.1. Product Type |
2.2.2. Therapeutic Area |
2.2.3. End User |
3. Global Peptide API CMO Market Dynamics |
3.1. Global Peptide API CMO Market - Macro-Economic Factors |
3.2. Global Peptide API CMO Market Dynamic Factors - Impact Analysis |
3.3. Global Peptide API CMO Market Dynamic Factors – Market Background |
3.3.1. Drivers and Restraints |
3.3.2. Opportunities/Unmet Needs of the Market & Trends |
3.4. Value Added Insights (USPs) |
4. Global Peptide API CMO Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Peptide API CMO Market, By Product Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Peptide Generic API |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Peptide NCEs |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6. Global Peptide API CMO Market Forecast, By Therapeutic Area, 2019 - 2023 and Forecast, 2024 - 2030 |
6.1. Oncology |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Cardiovascular Disorders |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Metabolic Disorders |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. CNS Disorders |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Respiratory Disorders |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.2.1. Market Opportunity Analysis |
6.6. Gastrointestinal Disorders |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Anti-infective Drugs |
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
6.8. Dermatology |
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.8.2.1. Market Opportunity Analysis |
6.9. Renal Disorders |
6.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.9.3. Market Opportunity Analysis |
6.10. Others |
6.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.10.2.1. Market Opportunity Analysis |
7. Global Peptide API CMO Market Forecast, By End User, 2019 - 2023 and Forecast, 2024 - 2030 |
7.1. Pharmaceutical Companies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Biopharmaceutical Companies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Peptide API CMO Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Peptide API CMO Market - Opportunity Analysis Index, By Product Type, Therapeutic Area, End User, and Region, 2024 - 2030 |
9. North America Peptide API CMO Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. By Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Peptide Generic API |
9.1.2. Peptide NCEs |
9.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. Oncology |
9.2.2. Cardiovascular Disorders |
9.2.3. Metabolic Disorders |
9.2.4. CNS Disorders |
9.2.5. Respiratory Disorders |
9.2.6. Gastrointestinal Disorders |
9.2.7. Anti-infectives |
9.2.8. Dermatology |
9.2.9. Renal Disorders |
9.2.10. Others |
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Pharmaceutical Companies |
9.3.2. Biopharmaceutical Companies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. U.S. |
9.4.2. Canada |
9.5. North America Peptide API CMO Market - Opportunity Analysis Index, By Product Type, Therapeutic Area, End User, and Country, 2024 - 2030 |
9.6. North America Peptide API CMO Market Dynamics – Trends |
10. Europe Peptide API CMO Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. By Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Peptide Generic API |
10.1.2. Peptide NCEs |
10.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Oncology |
10.2.2. Cardiovascular Disorders |
10.2.3. Metabolic Disorders |
10.2.4. CNS Disorders |
10.2.5. Respiratory Disorders |
10.2.6. Gastrointestinal Disorders |
10.2.7. Anti-infectives |
10.2.8. Dermatology |
10.2.9. Renal Disorders |
10.2.10. Others |
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Pharmaceutical Companies |
10.3.2. Biopharmaceutical Companies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Poland |
10.4.8. Rest of Europe |
10.5. Europe Peptide API CMO Market - Opportunity Analysis Index, By Product Type, Therapeutic Area, End User, and Country, 2024 - 2030 |
10.6. Europe Peptide API CMO Market Dynamics – Trends |
11. Asia-Pacific Peptide API CMO Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. By Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Peptide Generic API |
11.1.2. Peptide NCEs |
11.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Oncology |
11.2.2. Cardiovascular Disorders |
11.2.3. Metabolic Disorders |
11.2.4. CNS Disorders |
11.2.5. Respiratory Disorders |
11.2.6. Gastrointestinal Disorders |
11.2.7. Anti-infectives |
11.2.8. Dermatology |
11.2.9. Renal Disorders |
11.2.10. Others |
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Pharmaceutical Companies |
11.3.2. Biopharmaceutical Companies |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Japan |
11.4.2. China |
11.4.3. India |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Peptide API CMO Market - Opportunity Analysis Index, By Product Type, Therapeutic Area, End User, and Country, 2024 - 2030 |
11.6. Asia-Pacific Peptide API CMO Market Dynamics – Trends |
12. Latin America Peptide API CMO Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. By Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Peptide Generic API |
12.1.2. Peptide NCEs |
12.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Oncology |
12.2.2. Cardiovascular Disorders |
12.2.3. Metabolic Disorders |
12.2.4. CNS Disorders |
12.2.5. Respiratory Disorders |
12.2.6. Gastrointestinal Disorders |
12.2.7. Anti-infectives |
12.2.8. Dermatology |
12.2.9. Renal Disorders |
12.2.10. Others |
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Pharmaceutical Companies |
12.3.2. Biopharmaceutical Companies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Venezuela |
12.4.5. Rest of Latin America |
12.5. Latin America Peptide API CMO Market - Opportunity Analysis Index, By Product Type, Therapeutic Area, End User, and Country, 2024 - 2030 |
12.6. Latin America Peptide API CMO Market Dynamics – Trends |
13. Middle East and Africa Peptide API CMO Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
13.1. By Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Peptide Generic API |
13.1.2. Peptide NCEs |
13.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Oncology |
13.2.2. Cardiovascular Disorders |
13.2.3. Metabolic Disorders |
13.2.4. CNS Disorders |
13.2.5. Respiratory Disorders |
13.2.6. Gastrointestinal Disorders |
13.2.7. Anti-infectives |
13.2.8. Dermatology |
13.2.9. Renal Disorders |
13.2.10. Others |
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Pharmaceutical Companies |
13.3.2. Biopharmaceutical Companies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Peptide API CMO Market - Opportunity Analysis Index, By Product Type, Therapeutic Area, End User, and Country, 2024 - 2030 |
13.6. MEA Peptide API CMO Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Therapeutic Area & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. ScinoPharm Taiwan, Ltd. (Taiwan) |
14.2.2. Corden Pharma International (Germany) |
14.2.3. Bachem AG (Switzerland) |
14.2.4. Biopeptek Pharmaceuticals LLC. (U.S.) |
14.2.5. Hybio Pharmaceutical Co., Ltd. (China) |
14.2.6. Chinese Peptide Company (China) |
14.2.7. AmbioPharm, Inc. (U.S.) |
14.2.8. Teva Pharmaceutical Industries Ltd. (Israel) |
14.2.9. PolyPeptide Group (Sweden) |
14.2.10. Chemi S.p.A. (Italy) |
15. Research Methodology |
16. Key Assumptions and Acronyms |